Skip to main content
Heranba Industries Limited logo

Heranba Industries Limited — Investor Relations & Filings

Ticker · HERANBA ISIN · INE694N01015 LEI · 335800OPXIEPYCNRWS37 BSE.NS Manufacturing
Open in API
Filings indexed 442 across all filing types
Latest filing 2024-05-27 Investor Presentation
Country IN India
Listing BSE.NS HERANBA

About Heranba Industries Limited

https://www.heranba.co.in/

Heranba Industries Limited specializes in the manufacturing and marketing of synthetic pyrethroids and their intermediates. The company operates an integrated business model spanning the production of technicals, formulations, and branded products. Its extensive portfolio includes key active ingredients such as Cypermethrin, Deltamethrin, Alpha Cypermethrin, and Permethrin, catering to agriculture, public health, and animal health sectors. With multiple manufacturing facilities and dedicated R&D capabilities, the company provides a wide range of insecticides, herbicides, and fungicides. Heranba maintains a global footprint, supplying products to over sixty countries while ensuring quality control from intermediate stages to final crop protection solutions.

Recent filings

Filing Released Lang Actions
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation-Financial Overview-Q3 of FY2024' and is addressed pursuant to SEBI regulations, indicating it is an official investor communication. It contains detailed sections such as Company Overview, Management Team, Quarterly Performance, Financial Performance, and Strategy for Growth. The content includes financial data, management commentary, and business strategy, typical of an investor presentation. The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the report itself. There is no indication that this is a full annual report (10-K) or an interim report with full financial statements, but rather a presentation aimed at investors summarizing quarterly and yearly financial performance and outlook. Therefore, the most appropriate classification is Investor Presentation (IP).
2024-05-27 English
Financial Result Updates
Regulatory Filings Classification · 95% confidence The document is a formal communication from the company to stock exchanges reporting the outcome of a Board Meeting held on May 27, 2024. It includes approval of financial results for the quarter and year ended March 31, 2024, along with the auditor's report. It also mentions dividend declaration, AGM scheduling, and appointments of auditors. The document is structured as an announcement of these decisions rather than the full financial report itself. It references the financial results and auditor's report but does not contain detailed financial statements or analysis. The length is about 15,000 characters, which is substantial but the content is primarily an announcement of board meeting outcomes and related corporate actions. Therefore, this fits best as a Regulatory Filing (RNS) under SEBI Listing Regulations, reporting the outcome of the board meeting and financial results approval, rather than the full Annual Report (10-K) or Interim Report (IR).
2024-05-27 English
Outcome of Board Meeting
Regulatory Filings Classification · 95% confidence The document is a formal communication from the company to stock exchanges dated May 27, 2024, reporting the outcome of a Board Meeting. It includes approval of financial results for the quarter and year ended March 31, 2024, along with the auditor's report. It also mentions a dividend recommendation, details about the upcoming Annual General Meeting, record dates, and appointments of auditors. The document is an announcement of these decisions and results rather than the full financial report itself. It references the auditor's report and financial results but does not contain the full detailed financial statements or comprehensive analysis. The length is about 15,000 characters, which is substantial but the content is primarily an announcement of the board meeting outcomes and related corporate actions. Therefore, this fits best as a Regulatory Filing (RNS) because it is a regulatory announcement of financial results and corporate decisions, not the full Annual Report (10-K) or Interim Report (IR).
2024-05-27 English
Dividend
Regulatory Filings Classification · 95% confidence The document is a formal communication from the company to stock exchanges reporting the outcome of a Board Meeting held on May 27, 2024. It includes approval of financial results for the quarter and year ended March 31, 2024, along with the auditor's report. It also mentions dividend declaration, AGM scheduling, and appointments of auditors. The document is an announcement of these outcomes rather than the full financial report itself. The length is about 15,000 characters, but the content is primarily an announcement of results and decisions, not the detailed financial statements or management discussion. Therefore, it fits best as a Regulatory Filing (RNS) under SEBI Listing Regulations, reporting the board meeting outcomes and financial results approval, rather than the full Annual Report (10-K) or Interim Report (IR).
2024-05-27 English
Copy of Newspaper Publication
Regulatory Filings
2024-05-21 English
Board Meeting — HERANBA INDUSTRIES LIMITED has informed the Exchange about Board Meeting to be held on 27-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the…
Regulatory Filings
2024-05-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.